MapLight's Autism Drug Trial Fails to Meet Primary Endpoint
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2026
0mins
Source: NASDAQ.COM
- Trial Outcome Disappointment: MapLight Therapeutics' IRIS Phase 2 trial failed to meet its primary endpoint regarding social communication deficits in autism spectrum disorder, as the study of 161 participants did not show improvement in caregiver-reported scores over 12 weeks, indicating the need for further validation of the drug's efficacy in this area.
- Subgroup Analysis Shows Improvement: Despite the overall disappointing results, ML-004 demonstrated clinically meaningful improvement over placebo in adolescents (ages 12-17) with moderate or greater baseline irritability, suggesting potential efficacy in specific populations.
- Good Safety Profile: ML-004 was generally well-tolerated in the active treatment group, with no severe or serious adverse events reported, highlighting the drug's safety advantage and providing a foundation for future clinical development.
- FDA Follow-Up Plans: The company plans to engage with the U.S. FDA for an End-of-Phase 2 meeting after a full data review, exploring future clinical development pathways, indicating that despite the trial's failure to meet its primary endpoint, there may still be opportunities for development in targeted populations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MPLT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MPLT
Wall Street analysts forecast MPLT stock price to fall
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 37.060
Low
28.00
Averages
31.00
High
34.00
Current: 37.060
Low
28.00
Averages
31.00
High
34.00
About MPLT
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. It is also advancing two preclinical programs, ML-021 and ML-009.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
Raymond James Initiates Strong Buy Ratings for Tonix and MapLight
- Strong Buy Ratings: Raymond James has initiated coverage on Tonix Pharmaceuticals (TNXP) and MapLight Therapeutics (MPLT), assigning price targets of $26 and $46 per share respectively, with expectations that upcoming catalysts will drive stock price increases.
- FDA Meeting Outlook: Analyst Tiago Fauth noted that Tonix is set to meet with the FDA in Q3 2026 to discuss the Phase 2 trial design for its Lyme disease candidate TNX-4800, which could serve as an adoption-friendly seasonal prevention option for motivated risk groups, enhancing its market competitiveness.
- Commercial Update Anticipation: Fauth expects Tonix to release its first commercial update on Tonmya in Q2 2026, which is the first FDA-approved fibromyalgia therapy in over 15 years, projecting peak sales of $400M to $500M, thereby providing a supportive floor for TNXP shares.
- MapLight Catalyst: MapLight's ML-007C-MA, targeting schizophrenia and Alzheimer's disease psychosis, is expected to have its mid-stage trial results released in mid-August, with the analyst suggesting that this readout is skewed to the upside and could emerge as a significant value driver for the company.
See More
MapLight Therapeutics Appoints New Board Members
- New Board Members: MapLight Therapeutics elected Martin Babler and Troy Cox to its Board of Directors during the Annual Meeting on June 23, 2026, succeeding Robert Malenka and Jim Trenkle, indicating ongoing governance enhancements within the company.
- Committee Appointments: Babler joins the Audit Committee while Cox becomes Chair of the Nominating and Corporate Governance Committee, with their extensive biotechnology experience poised to support the company's strategic execution in developing therapies for CNS disorders.
- Rich Leadership Background: Babler has served as CEO of Alumis Inc. and held key positions at Principia Biopharma and Genentech, while Cox has executive experience at Foundation Medicine and Genentech, enhancing MapLight's competitive edge in the biopharmaceutical sector.
- Company Vision: MapLight focuses on developing innovative therapies for CNS disorders, aiming to fill existing pharmacotherapy gaps, and its discovery platform is expected to drive clinical advancements that improve patient quality of life.
See More
MapLight's Autism Drug Trial Fails to Meet Primary Endpoint
- Trial Outcome Disappointment: MapLight Therapeutics' IRIS Phase 2 trial failed to meet its primary endpoint regarding social communication deficits in autism spectrum disorder, as the study of 161 participants did not show improvement in caregiver-reported scores over 12 weeks, indicating the need for further validation of the drug's efficacy in this area.
- Subgroup Analysis Shows Improvement: Despite the overall disappointing results, ML-004 demonstrated clinically meaningful improvement over placebo in adolescents (ages 12-17) with moderate or greater baseline irritability, suggesting potential efficacy in specific populations.
- Good Safety Profile: ML-004 was generally well-tolerated in the active treatment group, with no severe or serious adverse events reported, highlighting the drug's safety advantage and providing a foundation for future clinical development.
- FDA Follow-Up Plans: The company plans to engage with the U.S. FDA for an End-of-Phase 2 meeting after a full data review, exploring future clinical development pathways, indicating that despite the trial's failure to meet its primary endpoint, there may still be opportunities for development in targeted populations.
See More
FCPM III Reduces Stake in Dyne Therapeutics by $14 Million
- Stake Reduction Details: On May 15, 2026, FCPM III Services B.V. sold 818,460 shares of Dyne Therapeutics, valued at approximately $14.11 million, indicating that despite the reduction, the fund maintains a significant position of 11.8% in the company.
- Market Performance Analysis: As of May 14, 2026, Dyne Therapeutics shares were priced at $18.28, reflecting a 56% increase over the past year, outperforming the S&P 500 by 28 percentage points, showcasing the company's robust growth potential in the biotechnology sector.
- R&D Progress Update: Dyne recently submitted a Biologics License Application to the FDA for its lead drug z-rostudirsen, targeting a potential U.S. launch in Q1 2027 if accelerated approval is granted, marking a significant milestone in muscle disease treatment.
- Investor Considerations: Despite the stake reduction, Dyne remains FCPM's second-largest holding, reflecting the fund's confidence in the company's future, particularly at a pivotal moment for translating clinical data into commercial success.
See More
Wall Street's Latest Rating Changes Overview
- Openlane Upgrade: JPMorgan upgraded Openlane from neutral to overweight and raised its December 2026 price target to $38, indicating that the online used car marketplace is experiencing robust growth and has potential for sustainable expansion over the coming years.
- Dollar General Downgrade: Deutsche Bank downgraded Dollar General from buy to hold, citing challenges in its customer base and the widening gap in the K-shaped economy, which may limit same-store sales upside, reflecting a cautious outlook on the company.
- Ecolab Upgrade: UBS upgraded Ecolab from neutral to buy and raised its price target to $325, demonstrating strong demand and positive performance expectations for the chemicals company amid a favorable market environment.
- FedEx Upgrade: JPMorgan upgraded FedEx from neutral to overweight, expressing optimism ahead of its upcoming earnings report, particularly regarding the separation of its freight business, which is seen as an attractive risk-reward opportunity.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
Raymond James Initiates Strong Buy Ratings for Tonix and MapLight
- Strong Buy Ratings: Raymond James has initiated coverage on Tonix Pharmaceuticals (TNXP) and MapLight Therapeutics (MPLT), assigning price targets of $26 and $46 per share respectively, with expectations that upcoming catalysts will drive stock price increases.
- FDA Meeting Outlook: Analyst Tiago Fauth noted that Tonix is set to meet with the FDA in Q3 2026 to discuss the Phase 2 trial design for its Lyme disease candidate TNX-4800, which could serve as an adoption-friendly seasonal prevention option for motivated risk groups, enhancing its market competitiveness.
- Commercial Update Anticipation: Fauth expects Tonix to release its first commercial update on Tonmya in Q2 2026, which is the first FDA-approved fibromyalgia therapy in over 15 years, projecting peak sales of $400M to $500M, thereby providing a supportive floor for TNXP shares.
- MapLight Catalyst: MapLight's ML-007C-MA, targeting schizophrenia and Alzheimer's disease psychosis, is expected to have its mid-stage trial results released in mid-August, with the analyst suggesting that this readout is skewed to the upside and could emerge as a significant value driver for the company.
See More
MapLight Therapeutics Appoints New Board Members
- New Board Members: MapLight Therapeutics elected Martin Babler and Troy Cox to its Board of Directors during the Annual Meeting on June 23, 2026, succeeding Robert Malenka and Jim Trenkle, indicating ongoing governance enhancements within the company.
- Committee Appointments: Babler joins the Audit Committee while Cox becomes Chair of the Nominating and Corporate Governance Committee, with their extensive biotechnology experience poised to support the company's strategic execution in developing therapies for CNS disorders.
- Rich Leadership Background: Babler has served as CEO of Alumis Inc. and held key positions at Principia Biopharma and Genentech, while Cox has executive experience at Foundation Medicine and Genentech, enhancing MapLight's competitive edge in the biopharmaceutical sector.
- Company Vision: MapLight focuses on developing innovative therapies for CNS disorders, aiming to fill existing pharmacotherapy gaps, and its discovery platform is expected to drive clinical advancements that improve patient quality of life.
See More
MapLight's Autism Drug Trial Fails to Meet Primary Endpoint
- Trial Outcome Disappointment: MapLight Therapeutics' IRIS Phase 2 trial failed to meet its primary endpoint regarding social communication deficits in autism spectrum disorder, as the study of 161 participants did not show improvement in caregiver-reported scores over 12 weeks, indicating the need for further validation of the drug's efficacy in this area.
- Subgroup Analysis Shows Improvement: Despite the overall disappointing results, ML-004 demonstrated clinically meaningful improvement over placebo in adolescents (ages 12-17) with moderate or greater baseline irritability, suggesting potential efficacy in specific populations.
- Good Safety Profile: ML-004 was generally well-tolerated in the active treatment group, with no severe or serious adverse events reported, highlighting the drug's safety advantage and providing a foundation for future clinical development.
- FDA Follow-Up Plans: The company plans to engage with the U.S. FDA for an End-of-Phase 2 meeting after a full data review, exploring future clinical development pathways, indicating that despite the trial's failure to meet its primary endpoint, there may still be opportunities for development in targeted populations.
See More
FCPM III Reduces Stake in Dyne Therapeutics by $14 Million
- Stake Reduction Details: On May 15, 2026, FCPM III Services B.V. sold 818,460 shares of Dyne Therapeutics, valued at approximately $14.11 million, indicating that despite the reduction, the fund maintains a significant position of 11.8% in the company.
- Market Performance Analysis: As of May 14, 2026, Dyne Therapeutics shares were priced at $18.28, reflecting a 56% increase over the past year, outperforming the S&P 500 by 28 percentage points, showcasing the company's robust growth potential in the biotechnology sector.
- R&D Progress Update: Dyne recently submitted a Biologics License Application to the FDA for its lead drug z-rostudirsen, targeting a potential U.S. launch in Q1 2027 if accelerated approval is granted, marking a significant milestone in muscle disease treatment.
- Investor Considerations: Despite the stake reduction, Dyne remains FCPM's second-largest holding, reflecting the fund's confidence in the company's future, particularly at a pivotal moment for translating clinical data into commercial success.
See More
Wall Street's Latest Rating Changes Overview
- Openlane Upgrade: JPMorgan upgraded Openlane from neutral to overweight and raised its December 2026 price target to $38, indicating that the online used car marketplace is experiencing robust growth and has potential for sustainable expansion over the coming years.
- Dollar General Downgrade: Deutsche Bank downgraded Dollar General from buy to hold, citing challenges in its customer base and the widening gap in the K-shaped economy, which may limit same-store sales upside, reflecting a cautious outlook on the company.
- Ecolab Upgrade: UBS upgraded Ecolab from neutral to buy and raised its price target to $325, demonstrating strong demand and positive performance expectations for the chemicals company amid a favorable market environment.
- FedEx Upgrade: JPMorgan upgraded FedEx from neutral to overweight, expressing optimism ahead of its upcoming earnings report, particularly regarding the separation of its freight business, which is seen as an attractive risk-reward opportunity.
See More
